{"pageContent": "Introduction: Prostate cancer is the most common solid organ malignancy in men in the United States. Until recently, treatment options for men with metastatic disease were limited and patients faced poor outcomes with minimal alternatives. The landscape of prostate cancer treatment has transformed and taken shape over the last 20 years with novel hormonal and non-hormonal therapeutics that have demonstrated significant improvement in survival. However, patients with advanced disease still face imminent progression on hormone blockade therapy.", "metaData": {"source": "The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)\nhttps://pubmed.ncbi.nlm.nih.gov/26409187/"}}